Compare OPAL & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | QNCX |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.3M | 139.2M |
| IPO Year | N/A | 2019 |
| Metric | OPAL | QNCX |
|---|---|---|
| Price | $2.52 | $3.80 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $2.81 | ★ $7.75 |
| AVG Volume (30 Days) | 184.4K | ★ 1.1M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $329,243,000.00 | N/A |
| Revenue This Year | $17.15 | N/A |
| Revenue Next Year | $22.04 | N/A |
| P/E Ratio | $114.93 | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $1.26 | $0.72 |
| 52 Week High | $4.08 | $4.55 |
| Indicator | OPAL | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 64.26 |
| Support Level | $2.50 | $3.74 |
| Resistance Level | $2.74 | $4.55 |
| Average True Range (ATR) | 0.15 | 0.46 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 62.83 | 64.39 |
OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.